CJC-1295 Modified GHRH Peptide Research
CJC-1295 research — Modified GRF(1-29) with and without DAC, GHRH receptor agonism, growth hormone pulsatility, IGF-1 elevation, and combination protocol research with Ipamorelin.
Featured Research
In-depth research profiles with mechanisms of action, key findings, and peer-reviewed citations.
CJC-1295 Without DAC (Modified GRF 1-29)
Also known as: CJC-1295 no DAC, Mod GRF 1-29, Modified GRF(1-29)
CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The modifications (Ala at position 2 to D-Ala, Asn at position 8 to Gln, Ala at position 15 to Ala (retained), and Met at position 27 to Leu) confer resistance to DPP-4 and ...
Quick Facts
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Al...
MW: 3367.97 g/mol
CAS: 863288-34-0
Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 21 days. Moderat...
CJC-1295 With DAC (Drug Affinity Complex)
Also known as: CJC-1295 DAC, CJC-1295 with Drug Affinity Complex
CJC-1295 with DAC is the albumin-conjugating version of CJC-1295, featuring a Drug Affinity Complex (DAC) — a reactive maleimidopropionic acid group that forms a covalent bond with serum albumin after subcutaneous injection. This albumin conjugation dramatically extends the circulating half-life from approximately 30 minutes (without DAC) to 6-8 days, enabling sustained elevation of GH and IGF-1 f...
Quick Facts
Sequence: Modified GRF(1-29) with maleimidopropionic acid-DAC conjugat...
MW: ~3647.28 g/mol
CAS: 863288-34-0
Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 21 days. The DAC...
Latest Research Articles
Deep-dive articles from the System Peptides Research Network.
CJC-1295 + Ipamorelin: The Combination Research Protocol
Why CJC-1295 and Ipamorelin are combined in research — complementary receptor targets, synergistic GH release, and study...
Read Article Research ScienceGrowth Hormone Releasing Pathways: GHRH vs GHS-R Mechanisms
Two pathways, one outcome: how GHRH receptor and ghrelin receptor (GHS-R) signaling converge on growth hormone release, ...
Read Article Category RoundupGrowth Hormone Secretagogues: A Complete Research Guide
Everything researchers need to know about GH secretagogues — Ipamorelin, CJC-1295, GHRP-6, Tesamorelin, and how they dif...
Read ArticleResearch Applications
Key research categories and applications studied in the scientific literature.
Lean Mass & Body Composition
Frequently cited as the best overall stack (with Ipamorelin) for increasing growth hormone, promoting lean muscle growth and fat metabolism without significantly increasing hunger or cortisol.
Weight Loss & Fat Metabolism
CJC-1295/Ipamorelin combination increases the body's natural growth hormone production, helping reduce fat while maintaining or building lean muscle mass.
Sleep Optimization
Growth hormone releasing peptides stimulate GH release which peaks during deep sleep, leading to more restorative rest, better tissue repair, and increased energy.
Recovery & Healing
Growth hormone secretagogues boost natural GH levels, which speeds up tissue repair and reduces recovery time between workouts in preclinical models.
Anti-Aging & Longevity
Often used together with Ipamorelin to boost natural growth hormone production, aiding in better sleep, fat loss, and muscle repair — key anti-aging markers.
Frequently Asked Questions
Common questions about cjc-1295 research research, purity standards, and sourcing.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH with four amino acid substitutions that improve stability and DPP-IV resistance. It comes in two forms: without DAC (short-acting) and with DAC (Drug Affinity Complex, long-acting).
What is the difference between CJC-1295 with and without DAC?
CJC-1295 without DAC (Mod GRF 1-29) has a half-life of ~30 minutes, producing acute GH pulses. CJC-1295 with DAC binds albumin via a maleimidopropionic acid linker, extending the half-life to ~8 days and producing sustained GH elevation.
Why is CJC-1295 combined with Ipamorelin?
CJC-1295 (GHRH agonist) and Ipamorelin (ghrelin receptor agonist) target complementary receptors on pituitary somatotrophs. The combination produces synergistic GH release — greater than either compound alone — while maintaining Ipamorelin's clean cortisol/prolactin-sparing profile.
Ready to Start Your Research?
Browse our complete research library or visit Research Vials to source peptides.
Explore the System Peptides Research Network